GlassScriptPhysician profile
Andrij O Baran
NPI 1962470724
$8,729.93
in general payments reported to CMS, 2019-2025
38 companies · $1,027 in 2025
The $1,027 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,153 · 2020: $649 · 2021: $1,157 · 2022: $1,944 · 2023: $1,546 · 2024: $1,254 · 2025: $1,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,826.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,284.89 | 2019-2025 | |
| Pfizer INC. | $1,120.16 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $587.40 | 2019-2024 | Xarelto |
| Alnylam Pharmaceuticals INC. | $533.52 | 2019-2025 | Onpattro |
| Abbott Laboratories | $497.56 | 2021-2025 | Cardiomems, Perclose Prostyle |
| Amgen INC. | $433.09 | 2019-2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $425.41 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $363.31 | 2020-2024 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $328.92 | 2020-2025 | Wainua, Farxiga, Lokelma |
| Cvrx, INC. | $321.43 | 2021-2024 | Barostim Neo System |
| Kiniksa Pharmaceuticals International, Plc | $300.38 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $260.46 | 2020-2025 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $244.04 | 2019-2023 | Lifevest |
| Merck Sharp & Dohme LLC | $227.75 | 2021-2025 | Verquvo |
| Amarin Pharma, INC. | $194.49 | 2019-2023 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrij Baran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.